Tag: Aquestive Therapeutics
FDA Denies Approval of Needle-Free Alternative to Epinephrine Auto-injectors
The rejection was unexpected based on feedback from the FDA's expert panel in June.
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data For Anaphylm™ (Epinephrine) Sublingual...
"Anaphylm allows patients to have medication with them where they need it, when they need it and is convenient enough to carry in their wallets or pockets.”
Anaphylm™, Aquestive’s Needleless Sublingual Epinephrine, Takes Another Step Forward
Company reports positive topline results from phase 2 study.
Sublingual Epinephrine Faster to Maximum Concentration than Auto-Injector, Syringe
Researchers observed early and robust increases in systolic and diastolic blood pressure and pulse with AQST-109.
Needle-Free, Sublingual Epinephrine Film Works Faster Than Auto-Injectors According to Study
Results from a 12mg formulation were comparable to intramuscular administration.
Aquestive Receives Positive FDA Response to Epinephrine Sublingual Film Phase 2...
Response confirms approach and supports the characterization of their novel drug platform.
Aquestive’s Sublingual Emergency Epinephrine Compares Favorably to EpiPen® in EPIPHAST II...
The company announced topline results from their EPIPHAST II study.
Aquestive Reports Positive Results from Sublingual Epinephrine Clinical Trial
Phase 2 study continues to show AQST-109 is safe and well tolerated.
They’re Coming: Needle-Free Emergency Epinephrine Options Currently in Trials
For some, the needle is a barrier to administration but alternatives are on the horizon.
Stealth Mode Company Granted Patent for Sublingual Epinephrine Tablet
We've been reporting on the progress of AQST-109 by Aquestive Therapeutics, a postage-stamp-sized film placed under the tongue that provides epinephrine in an anaphylactic...
